INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.
Mutations in the p53 gene are the most frequent genetic alterations in human tumours, occurring in approximately 50% of all cancers. The p53 protein is pivotal in maintaining genetic integrity after DNA damage, and alterations in the p53 pathway, including mutations in the p53 gene, greatly increase the probability of tumour formation. Gene therapy using adenoviral p53 has emerged as a novel treatment option, with the potential to be safe and effective in a wide range of cancer types. INGN 201 (Ad5CMV-p53, Advexin), a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Results show that Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents. In addition, there is now data to support the use of Advexin in cancer immunotherapy.
Gabrilovich
Dmitry I
DI
University of South Florida, H. Lee Moffitt Cancer Center and the Department of Interdisciplinary Oncology, MRC 2067, 12902 Magnolia Dr., Tampa, FL 33612, USA. dgabril@moffitt.usf.edu
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D008819:Mice, Nude; D009154:Mutation; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D014765:Viral Vaccines / Q000627:therapeutic use*
D014765:Viral Vaccines; C512972:advexin